ArticleJournal of clinical microbiology2016
Serological Diagnosis of Chronic Chagas Disease: Is It Time for a Change?
Article in Journal of clinical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Rapid diagnostic tests and ELISA for diagnosing chronic Chagas disease: Systematic revision and meta-analysis.PLoS neglected tropical diseases · 2022Pooled it
- Stage-InformedMicroorganisms · 2026Article
- Epitope mapping and conservation of antigens from the Multi-Cruzi immunoassay platform.Medical microbiology and immunology · 2026Article
- Host-Derived Molecules as Novel Chagas Disease Biomarkers: Hypercoagulability Markers and Extracellular Vesicles.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Target product profile for the development of pediatric formulations of new drugs for the treatment of children with T. cruzi infection.PLoS neglected tropical diseases · 2026Review
- Serological surveillance of orally acquired acute Chagas disease in the Brazilian Amazon using conventional and in house assays.Scientific reports · 2025Article
- TropD-detector a CRISPR/LbCas12a-based system for rapid screening of Trypanosoma cruzi in Chagas vectors and reservoirs.Scientific reports · 2025Article
- Serological determination of Trypanosoma cruzi in northern region of the State of Mexico.Parasitology research · 2025Article
- Utility of Magnetic Bead-Based Automated DNA Extraction to Improve Chagas Disease Molecular Diagnosis.International journal of molecular sciences · 2025Article
- Assessment of Alinity s ChagasLife (Basel, Switzerland) · 2024Article
- Article
- Prevalence ofEpidemiology and infection · 2023Article
- The Trypanosoma cruzi Antigen and Epitope Atlas: antibody specificities in Chagas disease patients across the Americas.Nature communications · 2023Article
- Proof of Concept of a Novel Multiepitope Recombinant Protein for the Serodiagnosis of Patients with Chagas Disease.Pathogens (Basel, Switzerland) · 2023Article
- Laboratory diagnosis ofFrontiers in parasitology · 2023Review
- Worldwide Control and Management of Chagas Disease in a New Era of Globalization: a Close Look at Congenital Trypanosoma cruzi Infection.Clinical microbiology reviews · 2022Review
- Parasitological, serological and molecular diagnosis of acute and chronic Chagas disease: from field to laboratory.Memorias do Instituto Oswaldo Cruz · 2022Article
- Air in the tires: towards an achievable, efficacious and timely diagnosis for Chagas disease.Memorias do Instituto Oswaldo Cruz · 2022Article
- Assessment of Liaison XL Murex Chagas diagnostic performance in blood screening for Chagas disease using a reference array of chimeric antigens.Transfusion · 2021Article
- Disagreement between PCR and serological diagnosis of Trypanosoma cruzi infection in blood donors from a Colombian endemic region.Biomedica : revista del Instituto Nacional de Salud · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease has spread to areas that are nonendemic for the disease with human migration. Since no single reference standard test is available, serological diagnosis of chronic Chagas disease requires at least two tests. New-generation techniques have significantly improved the accuracy of Chagas disease diagnosis by the use of a large mixture of recombinant antigens with different detection systems, such as chemiluminescence. The aim of the present study was to assess the overall accuracy of a new-generation kit, the Architect Chagas (cutoff, ≥1 sample relative light units/cutoff value [S/CO]), as a single technique for the diagnosis of chronic Chagas disease. The Architect Chagas showed a sensitivity of 100% (95% confidence interval [CI], 99.5 to 100%) and a specificity of 97.6% (95% CI, 95.2 to 99.9%). Five out of six false-positive serum samples were a consequence of cross-reactivity with Leishmania spp., and all of them achieved results of <5 S/CO. We propose the Architect Chagas as a single technique for screening in blood banks and for routine diagnosis in clinical laboratories. Only gray-zone and positive sera with a result of ≤6 S/CO would need to be confirmed by a second serological assay, thus avoiding false-positive sera and the problem of cross-reactivity with Leishmania species. The application of this proposal would result in important savings in the cost of Chagas disease diagnosis and therefore in the management and control of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.